长非编码RNAs: 乳腺癌中干部的关键调节者
Olivia Tellez-Jimenez1,2, Alejandro Ordaz-Ramos1, Marco Antonio Fonseca-Montaño3
1Laboratorio de Resistencia Tumoral y Metástasis en Medicina Traslacional, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Frontiers in cell and developmental biology
|November 3, 2025
概括
长非编码RNAs (lncRNAs) 是乳腺癌干细胞 (CSCs) 的关键调节者,影响治疗耐药性和复发. 了解 lncRNA 机制为乳腺癌管理提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 乳腺癌是全球女性死亡的主要原因之一.
- 治疗耐药性,复发和转移是乳腺癌管理的重大挑战.
- 癌症干细胞 (CSCs) 参与了这些挑战,但监管机制尚不清楚.
研究的目的:
- 审查当前关于非编码RNA (lncRNAs) 调节乳腺CSC的时间长度的知识.
- 突出 lncRNAs 作为乳腺癌治疗标和生物标记物的潜力.
主要方法:
- 关于lncRNAs和乳腺CSCs的研究的文献综述.
- 对IncRNA功能在干性调节中的分子机制的分析.
- 对基因表达和细胞局部化中的lncRNA作用的发现进行综合.
主要成果:
- lncRNAs在维持乳腺CSCs的茎状表型方面发挥着至关重要的作用.
- lncRNA的功能受其亚细胞局部 (细胞核,细胞质) 的影响.
- lncRNAs的失调有助于乳腺癌的治疗耐药性和转移.
结论:
- lncRNAs是乳腺CSC种群的关键调节者.
- 针对 lncRNAs 是克服治疗耐药性和改善乳腺癌结果的有希望的策略.
- 对lncRNA机制的进一步研究可以确定新的生物标志物和治疗途径.
相关概念视频
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
lncRNA - Long Non-coding RNAs
3.5K
3.5K
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs
23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K

